Decheng Capital Research
Investment Thesis
Decheng Capital is a global life sciences investment firm founded in 2012 and headquartered in Menlo Park, CA, with additional offices in Shanghai and New York. The firm describes its mission as providing capital and strategic support to early-stage life science companies with revolutionary technologies and growth-stage healthcare companies with strong market presence. Decheng's stated thesis is to capitalize on the rapid growth of the healthcare industry and breakthroughs in life science research, positioning itself as a "preferred partner for entrepreneurs, world-class scientists and strategic partners." A defining feature of the firm's strategy is a cross-border focus, leveraging deep networks and market access in both the United States and China to source and support healthcare and life science companies.
Stage Focus
Decheng invests across the company lifecycle, from early-stage private rounds (seed, Series A) through growth equity and into public-market follow-on investing (the portfolio includes numerous companies the firm backed pre-IPO and continued to hold or add to post-listing). The firm is comfortable investing in companies with "revolutionary technologies" pre-revenue as well as growth-stage healthcare businesses that already have commercial traction.
Check Size
No explicit check-size range is published on the firm's site. Third-party coverage describes the firm's range as spanning pre-seed to growth equity, consistent with a multi-stage life sciences generalist. Existing F4-OS records show a working range of roughly $5M-$20M per investment, which is a reasonable mid-range estimate for a firm of this AUM but should be treated as a moderate-confidence estimate absent a primary-source figure.
Lead Tendency
Decheng frequently leads or co-leads syndicates. Most recently, Decheng led the ~$100M private placement financing for Remix Therapeutics (announced June 24, 2026, ahead of its reverse merger with Passage Bio and Nasdaq listing as RMTX), with participation from Lynx1 Capital Management, Forge Life Science Partners, and other investors. This lead role is consistent with the firm's pattern in earlier rounds like Aardvark Therapeutics' oversubscribed $85M Series C.
Recent Activity
Decheng has been actively deploying, with 2 new investments in 2025 and 2 more logged as of March 2026, and its most recent disclosed investment (Remix Therapeutics) closing in June 2026. The firm is simultaneously in market with its fifth flagship fund, Decheng Capital Global Life Sciences Fund V, targeting $700M (larger than the $650M target for its 2020-vintage predecessor fund); as of an October 2025 SEC filing, the fund had raised roughly $450M toward that target, indicating the fund is still actively fundraising and deploying rather than fully closed.
Portfolio Highlights
Decheng's portfolio spans roughly 80+ companies with a strong exit track record: 18+ IPOs and 19+ acquisitions, including marquee names like Invitae, Adaptive Biotechnologies, and GRAIL (acquired by Illumina). Standout recent exits include Prometheus Biosciences (acquired by Merck for $10.8B, closed June 2023) and Alpine Immune Sciences (acquired by Vertex Pharmaceuticals for ~$4.9B, announced April 2024). Other notable active portfolio companies include Mammoth Biosciences (CRISPR gene editing, with a $100M upfront Regeneron collaboration), Cellares (automated cell therapy manufacturing, with a $380M Bristol Myers Squibb supply deal), Upstream Bio, Hummingbird Bioscience, Mirvie, and Shape Therapeutics.
Team
- Min Cui, Ph.D. — Founder and Managing Director
- Victor Tong, Jr. — Managing Director
- Peter Colabuono — Managing Director
- Dayton Misfeldt — Partner
- Tony Tong, Ph.D. — Partner
- Qiang Xu, Ph.D. — Partner
- Wei Xu — Partner
- Aaron Li, MBA — Principal
- Shengyang Jin, Ph.D. — Vice President
- Michael Notaras, Ph.D. — Vice President
- Joan Chen, Ph.D. — Vice President
- Claire Zhang, M.B.A. — Senior Associate
- Nick Pliam, M.D., Ph.D. — Venture Partner
The firm's site does not publish individual bios, prior-firm history, or LinkedIn URLs, so founder-facing background beyond name, title, and academic credentials is not independently verifiable from the primary source.
Decision Process
With a partner-level team of this size (7 partners/MDs plus a bench of VPs and principals), Decheng operates as a partnership rather than a solo-GP shop. No public detail on decision timeline was found.
Founder Preferences
Decheng backs founding teams built around "revolutionary technologies," which in practice skews toward scientist-founders and academic spinouts (e.g., CRISPR platforms, novel modalities) as well as experienced healthcare operators building growth-stage commercial businesses. The firm's cross-border network makes it a natural fit for founders with US-China commercialization ambitions.
Geographic Focus
Primary geography is the United States (Silicon Valley HQ) and China (Shanghai office), with a New York office supporting East Coast biotech and capital-markets relationships. The firm explicitly positions cross-border US-China dealflow and market access as a differentiator.